32
Participants
Start Date
May 28, 2024
Primary Completion Date
April 5, 2026
Study Completion Date
April 5, 2026
3BNC117-LS-J
Administered by intravenous (IV) infusion
10-1074-LS-J
Administered by intravenous (IV) infusion
Placebo for 3BNC117-LS-J
Administered by intravenous (IV) infusion
Placebo for 10-1074-LS-J
Administered by intravenous (IV) infusion
Soweto HVTN CRS (30351), Soweto
Ward 21 CRS (31966), Johannesburg
CAPRISA eThekwini CRS (31422), Durban
Groote Schuur HIV CRS (31708), Cape Town
Gaborone CRS (12701), Molepolole
Blantyre CRS (30301), Blantyre
Lilongwe Malawi CRS (12001), Lilongwe
Aurum Institute Klerksdorp CRS (30325), Klerksdorp
Rustenburg CRS (31684), Rustenburg
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
NETWORK